Skip to content
Screener

Upstream Bio, Inc. UPB Q1 2026 earnings

Reported May 13, 2026 · Before market open

Revenue$1.0MBeat by $6.3K
EPS-$0.75Miss by $0.01
Revenue estimate$1.0M
EPS estimate-$0.74

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$522.5K
EPS estimate-$0.73

Financials

Q1 2026

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$489.78M+49.2%
Enterprise value$394.17M+52.4%
P/S147.4×+4.5×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%—
Debt / equity0×0.0×
Current ratio23.1×-24.3×

FAQ

When did Upstream Bio, Inc. report Q1 2026 earnings?
Upstream Bio, Inc. (UPB) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Upstream Bio, Inc.'s Q1 2026 revenue and EPS?
Upstream Bio, Inc. reported revenue of $1.0M and eps of $-0.75 for Q1 2026.
Did Upstream Bio, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.0M by $6.3K. EPS missed the consensus estimate of $-0.74 by $0.01.
How did Upstream Bio, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 82.7% from $566.0K a year earlier and eps declined 47.1% from $-0.51.
Where can I find Upstream Bio, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-220578) and the 10-Q periodic report (0001193125-26-220584) directly on SEC EDGAR. The filing index links above go to sec.gov.